Updates

Clinigen

March 2014

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Having been a mercurial riser Clinigen has succumbed to its first real sell off after interims that showed sales were up 6% to £61.8m, pretax profit up 12% to £10.9m and eps up 8% to 9.7p. I guess the bit investors didn't appreciate was the fact that the speciality product (SP) side has not yet launched all its acquired products and that there was lumpy business in both the SP and Clinical Trial Supply side last year, making for difficult comparables. Sales in SP were £12.3m but adjusting for distributor stocking in the prior year underlying sales were up £2.2m. As we have said before, Foscavir has achieved most of the high level growth; it has a third indication for bone marrow but can really only grow in line with the und ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Avation

Daily Internet - Son of Iomart

Clinigen (November 2016)

Clinigen (October 2016)

Clinigen (October 2015)

Clinigen (August 2015)

Clinigen - Completes £225m Idis acquisition (June 2015)

Clinigen (April 2015)

Clinigen (February 2015)

Clinigen - Acquires speciality products (September 2014)

Clinigen - Company reassures investors with trading update (August 2014)

Clinigen - Growing rapidly into valuation (February 2014)

Clinigen - On lookout for 3-5 more deals (November 2013)

Clinigen - Another upgrade to forecast (September 2013)

Clinigen - First of half a dozen deals (April 2013)

Clinigen - Acquisition anticipated in March (March 2013)

Clinigen - Trial services to grow at 17% annual clip (December 2012)

Clinigen - New issue growing like topsy (November 2012)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X